DROP-IN AND GO KBLB! HOLDING THE GOLDEN!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's hilariously dumb is remaining invested believing the stock couldn't possibly get there! 🙃🤪🙃
Thanks M4N! Love this from the article:
We still haven't sprung the "Exponential Acceleration" on the World yet! That's when your beloved Kraken will come to life, B-man! Tentacles flying everywhere!!! Scary Good Times Ahead!!!
You mean like this:
Good thing time was spent laying the foundation!
My guess is he was being facetious.
Both the history and potential of silk (Spider Silk, especially) in one article:
https://nextbigideaclub.com/magazine/silk-changed-history-might-change-future-bookbite/49793/
Silk Changed History–and It Might Change the Future Too
Aarathi Prasad
4 June, 2024
Just look at all the "biocompatibility" talk from this ARTIFICIAL SS claimant:
https://www.baltictimes.com/biomedical_start-up_printymed_plans_to_start_exporting_artificial_spider_silk_products_next_year/#
The Baltic Times
Biomedical start-up PrintyMed plans to start exporting artificial spider silk products next year
2024-06-07
Innovative biomedical start-up PrintyMed has developed an artificial spider silk, a unique biomaterial intended for diverse medical applications, including the creation of artificial organs to save numerous lives. Next year, the domestically developed cell-binding membrane, essential for "organ-on-chip" technology production, will be exported to Estonia, Finland, and the UK.
Offering a remarkable combination of lightweight, durability, and flexibility, artificial spider silk has versatile use across various sectors, from defense (bulletproof vests) to healthcare. "PrintyMed," a Latvian startup, has employed cutting-edge technology from the Institute of Organic Synthesis to biomimetically create artificial spider silk, which not only exhibits superior properties but is also biocompatible with the human body.
Heart disease claims millions of lives annually, with approximately one-third of global deaths attributed to heart and vascular conditions. To address this issue, over 300,000 heart valve replacement surgeries are performed each year, a number expected to rise to 500,000 in the near future. While there are around 6,000 organ transplants conducted annually, the demand far exceeds the supply, with 100,000 individuals currently awaiting a transplant. Furthermore, every ten minutes, a new patient joins the waiting list, and tragically, 22 people die daily while awaiting a transplant. Even when a transplant is received, there is a high risk of rejection due to autoimmune responses.
“Our spider silk is biocompatible within the human body, minimizing the risk of rejection and making it ideal for creating artificial organs using 3D bioprinters. At the moment our primary goal is to develop a functional artificial heart valve. Of course, it is still a long way off - three to five years - so as a first step we have developed a cell-binding membrane that offers innovative possibilities for drug testing," CEO of PrintyMed Jekaterina Romanova anticipates.
With the cell-binding membrane serving as the company's first export product, "PrintyMed" is actively collaborating with partners in Finland, Estonia, and the UK to tailor the technology to specific requirements. Artificial spider silk, boasting high cell-binding capabilities and biocompatibility, is well-suited for the development of advanced organs-on-chips, which serve as miniature organ models used in pharmaceutical and cosmetic research to expedite studies and reduce the reliance on animal models. It's also worth noting that the production process for artificial spider silk utilizes renewable resources, avoids pollution, and aligns with sustainable investment practices.
Statistics show that the market for "organs-on-a-chip" is currently witnessing rapid expansion and is forecasted to reach $1.6 billion by 2031, positioning it as a promising long-term investment. "PrintyMed" has already secured local support, receiving grants from the Latvian Investment and Development Agency and the European Union, and is actively pursuing international investors for its innovative product development. The company is actively engaged in various activities to attract potential investors, including showcasing artificial spider silk at significant industry events such as the "Deep Tech Atelier" in the Baltics. Partnerships have been established not only within Europe but also with Israel, particularly in the field of cardiology, which is crucial for the planned production of heart valves.
Despite the investors preference for quickly achievable goals in the medical field, "PrintyMed" remains committed to creating high-value products, such as 3D printing of artificial organs, which often requires considerable time and resources for clinical trials and testing.
"Producing heart valves from artificial spider silk is not a quick project, as it requires clinical trials and testing, but we are ready to give it our all, helping many people to improve their quality of life and even save lives," adds Romanova.
"PrintyMed" is a visionary biomedical technology startup focused on leveraging its unique biomaterial, artificial spider silk, to develop advanced medical products. With an exclusive license to produce artificial spider silk for medical purposes, the company is dedicated to creating artificial organs capable of replacing damaged organs and prolonging lives.
***********************
Move over "PrintyMed," KBLB is here!!!
We supporters, especially Mr. T, thank you for your continued investment in all that! Bunch of crazy investors we all are! Lol
Thanks! Now I have to buy a new drink! Tell me you did not type that with a straight face.
Because it's difficult means it's not happening? Sounds like your KBLB reasoning. More disinformation.
You've exposed the "Great Distractor!" He's not here to inform with facts. Rather, disinformation is his game. AI has become his new "tool" of choice over Google. To me, all it's done is make him more long-winded. Something I didn't think was possible.
***BALANCED PERSPECTIVE FOR NOTICE OF EFFECTIVENESS***
While this could lead to the issuance of new shares, it’s essential to understand the strategic context:
Capital for Growth: Issuing new shares can provide the necessary funds for advancing research, development, and commercialization efforts, especially for groundbreaking technologies like Spider Silk.
Strategic Dilution: Any dilution is likely a strategic move to secure funding essential for the company’s growth and long-term success, not an indiscriminate action. (Essentially what KBLB is noted for over the past 18 years).
Regulatory Approval: The effectiveness notice is a regulatory requirement for transparency and legal compliance in public offerings.
Understanding the broader context of such moves, especially for a company in a high-growth phase, is crucial for a balanced perspective.
Lol. Scary stuff! 😱
A pre-revenue (for the most part) development company on the verge of Mass Commercialization of its groundbreaking product may need additional funding? OH NO!!! We get it..."dilution" is BAD! 😱 What is worse for investors is not funding operations. That is VERY BAD! Thankfully, Mr. T won't let that happen. Unlike some, he has integrity!
Who's plan? It's OK to overlook the addressing of that. Because it sure looks like "coming weeks, " as it's been used currently, is hitting with regularity...
💥💥💥BAM! BAM! BAM!...💥💥💥
Just the unsuspecting ones. 🤣
Listen, dude, I don't care who you get to jump on the Troll Trolley with you, but, I am a little concerned for those unsuspecting souls who are not aware of the defamatory paths those Trolley tracks are taking them. It really shouldn't take the inevitable cease and desists for the Trolley to halt. But the choice lies with each individual. To each their own
Wait one...
If one can't tell boilerplate and forward-looking statements from material ones, then they really have no business investing. Or making various other decisions in other areas of life, in general. Wow!
LMAO! It's a standard boilerplate/CYA disclaimer...
Here are a few reasons why this type of statement is commonly used:
Disclosure Requirements: Publicly traded companies are required to disclose potential legal risks to investors. This statement helps meet regulatory requirements by acknowledging the existence of legal matters without going into specific details that may not be material.
Risk Management: It serves to manage investor expectations by indicating that legal issues are a normal part of business operations and are being monitored and addressed by the company.
Materiality: The phrase "none of which at the time are considered to be material" reassures investors that any current legal issues are not expected to significantly impact the company's financial stability or operational capabilities.
Standard Practice: Including such disclaimers is a standard practice across industries to provide a level of transparency while also protecting the company from potential legal liabilities.
Overall, this type of language is intended to provide a balanced view, acknowledging that while legal issues may occur, they are not anticipated to threaten the company’s viability.
Thanks for continuing to confirm the ongoing smear campaign against KBLB is "alive and kicking!" Let's hope when the cease and desists are handed out the same commitment to expressive beliefs is followed.
Nice timeline of moving forward events towards the first-ever sustainable company built around the Commercialization of Spider Silk. Of course, the infantile "failed" opinions will be laughed at for posterity as the company is celebrated for its achievements. That definitely can't be good for those KBLB trolls. Must be why all the grasping at straws for any piece of information to attempt to turn into a negative. The ultimate failure! 😁
You have high hopes that will do. I'm not as certain. That's why I will take every opportunity to expose their foolish notions at every level. From Development through full-scale, sustainable Commercialization.
So convinced every path leads to nowhere with KBLB yet devote so much time to ensuring others believe the same. Weird
"...stop and think..." 🤣
That's not the M.O.
They should patent it. At least then it might be worth something! 🤣
Promoting trolls and attempting to denigrate firms who know what they're doing above and beyond in the IP field, really works to expose that negative propaganda you continue to endorse. It might help to actually read AND UNDERSTAND what's being read in company communications. The company hinted at these moves months ago. But, to provide the Cliffs Notes, these moves were strategic. Not damaging. The decision to discontinue certain patents and focus on obtaining formal IP registration for the BAM-1 hybrid silkworm strain in Vietnam is likely a strategic move to optimize the company’s IP portfolio, financial resources, and market focus. This approach aligns with common business practices aimed at enhancing efficiency and ensuring robust protection of the most critical innovations. Addition by subtraction. Strength through removal. Yep, "good thing KBLB retained Workman Nydegger for their expertise in obtaining patents. Another great expense..."
THE REAL KBLB WAY:
💥💥BAM💥💥
Are trolls vegans? 🤣
Isn't that what "Prodigy Silk" will be utilized for?
Or am I reading this wrong:
The CEO’s actions, including deferred salary, accrued interest, and personal financial contributions, clearly demonstrate a commitment to the company’s growth and success. The claims suggesting otherwise lack substantiated evidence and misunderstand standard business practices.
The burden of proof lies with those making the unfounded allegations, not with those defending against them.
Now show us all unequivocally where those funds are not being redirected to company operations. We'll wait...
The CEO's actions, including deferring salary, providing personal loans, and accepting equity-based compensation, indicate a strong commitment to reinvesting in the company and ensuring its long-term success. There is no evidence to suggest that the CEO is "lining his pockets" for personal gain at the expense of the company. Instead, these actions align with standard practices aimed at supporting the company's growth and achieving its strategic goals.
Hopefully it's in sending cease and desists!
You might want to actually read the filings.
Incorrect. SALARY PLUS INTEREST:
Page 39 of the recent filing. Between 2016-23=$6.2M in "accrued salary." Just a sales contract or uplist away from "debt forgiveness." It was hinted at (well, more than hinted at) years ago by Mr. T, and considering he's still deferring,, expect him to follow through.
Funny all the reading between the lines but can't read this...
Under...RECENT DEVELOPMENTS, p.7, para. 2:
Nice deflection. Lol